Novartis Simulect May Offer Dosing Advantage to Roche's Zenapax
Executive Summary
Novartis is positioning its chimeric monoclonal antibody Simulect (basiliximab) as offering a dosing advantage over Roche/PDL's humanized MAb Zenapax (daclizumab), the company indicated in an April 15 announcement of Swiss approval for the renal transplant agent.